PTCT
PTC Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$69.30
−2.94%0
Insider buys (3m)
47
Insider sells (3m)
-$18.5M
Net value (3m)
-1.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 28, 2026 | SCHMERTZLER MICHAEL · director | Sale | 11,890 | $72 |
| Aug 28, 2026 | SCHMERTZLER MICHAEL · director | Sale | 5,626 | $73 |
| Aug 28, 2026 | SCHMERTZLER MICHAEL · director | Sale | 610 | $72 |
| Aug 28, 2026 | SCHMERTZLER MICHAEL · director | Sale | 6,874 | $73 |
| Aug 21, 2026 | SCHMERTZLER MICHAEL · director | Sale | 7,165 | $74 |
| Aug 21, 2026 | SCHMERTZLER MICHAEL · director | Sale | 9,419 | $71 |
| Aug 21, 2026 | SCHMERTZLER MICHAEL · director | Sale | 5,335 | $73 |
| Aug 21, 2026 | SCHMERTZLER MICHAEL · director | Sale | 2,390 | $72 |
| Aug 21, 2026 | SCHMERTZLER MICHAEL · director | Sale | 691 | $73 |
| Aug 19, 2026 | Boulding Mark Elliott · officer: EXEC. VP AND CLO | Sale | 969 | $73 |
| Aug 19, 2026 | Boulding Mark Elliott · officer: EXEC. VP AND CLO | Sale | 1,844 | $72 |
| Aug 19, 2026 | Boulding Mark Elliott · officer: EXEC. VP AND CLO | M-Exempt | 2,813 | $26 |
| Aug 6, 2026 | Klein Matthew B. · director, officer: CHIEF EXECUTIVE OFFICER | Sale | 10,292 | $69 |
| Jul 30, 2026 | Sollie-Zetlmayer Hege Elisabeth · director | A-Award | 4,000 | $0.00 |
| Jul 30, 2026 | Sollie-Zetlmayer Hege Elisabeth · director | A-Award | 1,738 | $75 |
| Jul 30, 2026 | Sollie-Zetlmayer Hege Elisabeth · director | A-Award | 3,475 | $75 |
| Jul 30, 2026 | Sollie-Zetlmayer Hege Elisabeth · director | A-Award | 2,000 | $0.00 |
| Jul 16, 2026 | Gravier Pierre · officer: CHIEF FINANCIAL OFFICER | Sale | 3,494 | $80 |
| Jul 13, 2026 | Smith Mary L. · director | M-Exempt | 10,000 | $43 |
| Jul 13, 2026 | Almstead Neil Gregory · officer: CHIEF TECHNICAL OPS OFFICER | M-Exempt | 2,464 | $47 |
| Jul 13, 2026 | Almstead Neil Gregory · officer: CHIEF TECHNICAL OPS OFFICER | Sale | 2,464 | $90 |
| Jul 13, 2026 | Smith Mary L. · director | Sale | 5,834 | $90 |
| Jul 13, 2026 | Smith Mary L. · director | M-Exempt | 5,834 | $43 |
| Jul 8, 2026 | Almstead Neil Gregory · officer: CHIEF TECHNICAL OPS OFFICER | M-Exempt | 24,613 | $39 |
| Jul 8, 2026 | Boulding Mark Elliott · officer: EXEC. VP AND CLO | Sale | 833 | $84 |
| Jul 8, 2026 | Almstead Neil Gregory · officer: CHIEF TECHNICAL OPS OFFICER | Sale | 10,090 | $86 |
| Jul 8, 2026 | Boulding Mark Elliott · officer: EXEC. VP AND CLO | Sale | 313 | $83 |
| Jul 8, 2026 | Boulding Mark Elliott · officer: EXEC. VP AND CLO | M-Exempt | 2,226 | $39 |
| Jul 8, 2026 | Boulding Mark Elliott · officer: EXEC. VP AND CLO | Sale | 387 | $83 |
| Jul 8, 2026 | Almstead Neil Gregory · officer: CHIEF TECHNICAL OPS OFFICER | Sale | 2,474 | $87 |
Institutional positioning
13F filings over the trailing two quarters
New 139Increased 288Reduced 219Sold out 45
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | Increased | 13,964,554 | Aug 7, 2026 |
| BLACKROCK, INC. | Increased | 12,948,717 | May 13, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 7,746,415 | Aug 14, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 7,746,415 | May 15, 2026 |
| Jupiter Topco LLC | New Position | 7,236,402 | Aug 14, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 7,193,433 | May 18, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 4,928,111 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 4,804,594 | May 8, 2026 |
| STATE STREET CORP | Increased | 4,598,952 | Aug 7, 2026 |
| STATE STREET CORP | Increased | 4,346,519 | May 15, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 4,128,273 | Aug 14, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Increased | 3,942,610 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 3,739,127 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 3,676,256 | May 15, 2026 |
| TORONTO DOMINION BANK | Reduced | 3,025,963 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 28, 2026